CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CRSP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.06B
- EPS (TTM)
- -$4.74
- Dividend yield
- None
- 52-week range
- 44.12 – 78.38
- Day range
- 52.27 – 54.59
- Volume / Avg
- 1.68M / 1.59M
- Beta
- —
- Shares outstanding
- 96.69M
52-week range
CRSP stock today
Shares of CRISPR Therapeutics (CRSP) finished lower on Oct 7 at $52.35, a drop of 3.06% or $1.65 per share, versus the S&P 500's 0.22% decline. At this level, CRSP sits in the middle of its 52-week range of $44.12 to $78.38: 33.2% below the high, set on Oct 8, 2025 and 18.7% above the low. CRSP is down 0.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 25.9%.
CRISPR Therapeutics has posted a net loss over the last twelve months (EPS of -$4.74), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CRISPR Therapeutics
Company profileCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Samarth Kulkarni Ph.D.
- Headquarters
- Zug
- IPO year
- 2016
- Website
- crisprtx.com
Financial highlights
Full financialsIn fiscal 2025, CRISPR Therapeutics generated $3.5 million in revenue, down 90.6% from fiscal 2024, its first annual decline since 2024. CRISPR Therapeutics reported a net loss of $581.6 million, compared with a loss of $366.3 million a year earlier. Operating margin was -18933.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.51M | $37.31M | $371.21M | $1.20M | $914.96M |
| Growth | -90.59% | -89.95% | +30885.48% | -99.87% | +127154.94% |
| Net income | $-581.60M | $-366.25M | $-153.61M | $-650.17M | $377.66M |
| EPS (diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
Analyst forecast
ForecastConsensus (22 analysts)
buy
Avg. price target
$87.56+67.26%
- Strong buy 5
- Buy 8
- Hold 9
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2026)
- Aug 3, 2026
- EPS actual vs est.
- $-0.94 vs —
CRSP news
All CRSP newsCRISPR Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SRRKScholar Rock Holding Corporation | 42.20 | -0.59% | $5.14B | vs CRSP |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs CRSP |
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs CRSP |
| IOVAIovance Biotherapeutics Inc. | 12.92 | -0.35% | $5.85B | vs CRSP |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs CRSP |
| RLAYRelay Therapeutics Inc. | 17.95 | -4.22% | $3.93B | vs CRSP |
| IMVTImmunovant Inc. | 32.04 | -0.22% | $6.62B | vs CRSP |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs CRSP |
Indexes, lists and sector
CRISPR Therapeutics stock FAQ
What is CRISPR Therapeutics's stock price today?
CRSP last traded at $52.35 as of Oct 7, 4:00 PM EDT, down 3.06% on the day. Prices are delayed at least 15 minutes.
Who is CRISPR Therapeutics's CEO?
Dr. Samarth Kulkarni Ph.D. is the chief executive officer of CRISPR Therapeutics AG.
What is the CRSP 52-week high?
The 52-week high for CRSP is $78.38 and the 52-week low is $44.12. The stock is currently 33.2% below its high.